3.1 Distance from BSMs to small-molecule drugs
The most important reason to study BSMs is that it provides an opportunity to be a potential medicine and clinical intervention. Although the development of bio-macromolecule drugs represented by monoclonal antibodies, such as PD-1 [85], is quite predominant at present, small-molecular drug holds about an 80% share of the global drug market. And since the monoclonal antibodies are complicated to product and difficult to store, the heterogeneity among the effectiveness of the drugs obtained by different methods limits its wide use. Hence, the drugs derived from BSMs would a good alternative in cardiovascular fields.